Search results
Results From The WOW.Com Content Network
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
This website is intended for people seeking information on AstraZeneca's worldwide business. Our country sites can be located in the AZ Network.
Join the team unlocking the power of science. We’re all working towards treating, preventing, modifying and curing some of the world’s most complex diseases. It’s our combination of curiosity and courage that drives us, inspired by the possibility of doing things that have never been done before.
In our Annual Report we report on the progress we made in 2021 in pushing the boundaries of science to deliver life-changing medicines. 01. 02 Strategic overview. 03 Disease Area Review. 04 Sustainability Highlights. 05 Achieve Group Financial Targets.
AstraZeneca’s deep pipeline of medicines focusing on their key therapeutic areas.
For medical enquiries about our products (including questions on how to take your medicine, to report a side effect or make a complaint regarding one of our medicines), please call our UK based Medical Information team on: 0800 783 0033. Lines are open from Monday-Friday, 9am-5pm.
Introducing AstraZeneca's Board of Directors, Senior Executives and Lead Scientists. Find information on each individual membership of the leadership team.
footprint. At AstraZeneca, we’re driving deep decarbonisation across our value chain through our flagship Ambition Zero Carbon strategy. We’re investing $1 billion to reduce emissions from the lab to the patient and are integrating more circular approaches into the discovery, development and delivery of medicines with the
Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients, society, the planet and our shareholders. Our ambition is to launch at least 15 new medicines by 2030. Three were approved in 2023.